308 related articles for article (PubMed ID: 32510244)
1. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Galluzzo M; Tofani L; Bianchi L; Talamonti M
Expert Opin Biol Ther; 2020 Aug; 20(8):829-830. PubMed ID: 32510244
[TBL] [Abstract][Full Text] [Related]
2. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications.
Loganathan S; Athalye SN; Joshi SR
Expert Opin Biol Ther; 2020 Sep; 20(9):1025-1031. PubMed ID: 32700604
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in an elderly patient treated with secukinumab.
Di Lernia V; Bombonato C; Motolese A
Dermatol Ther; 2020 Jul; 33(4):e13580. PubMed ID: 32406078
[No Abstract] [Full Text] [Related]
4. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.
Balestri R; Rech G; Girardelli CR
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e357-e358. PubMed ID: 32358791
[No Abstract] [Full Text] [Related]
5. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.
Wan MT; Shin DB; Winthrop KL; Gelfand JM
J Am Acad Dermatol; 2020 Aug; 83(2):677-679. PubMed ID: 32416207
[No Abstract] [Full Text] [Related]
6. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.
Coskun Benlidayi I; Kurtaran B; Tirasci E; Guzel R
Rheumatol Int; 2020 Oct; 40(10):1707-1716. PubMed ID: 32591970
[TBL] [Abstract][Full Text] [Related]
7. Improvement of SARS-CoV-2 symptoms following Guselkumab injection in a psoriatic patient.
Benhadou F; Del Marmol V
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e363-e364. PubMed ID: 32379925
[No Abstract] [Full Text] [Related]
8. Lessons from the Italian COVID-19 frontline.
Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
[No Abstract] [Full Text] [Related]
9. Biologic agents in psoriasis: our experience during coronavirus infection.
Strippoli D; Barbagallo T; Prestinari F; Russo G; Fantini F
Int J Dermatol; 2020 Aug; 59(8):e266-e267. PubMed ID: 32516447
[No Abstract] [Full Text] [Related]
10. Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Michot JM; Albiges L; Chaput N; Saada V; Pommeret F; Griscelli F; Balleyguier C; Besse B; Marabelle A; Netzer F; Merad M; Robert C; Barlesi F; Gachot B; Stoclin A
Ann Oncol; 2020 Jul; 31(7):961-964. PubMed ID: 32247642
[No Abstract] [Full Text] [Related]
11. Should biologics for psoriasis be interrupted in the era of COVID-19?
Lebwohl M; Rivera-Oyola R; Murrell DF
J Am Acad Dermatol; 2020 May; 82(5):1217-1218. PubMed ID: 32199889
[No Abstract] [Full Text] [Related]
12. How does COVID-19 kill? Uncertainty is hampering doctors' ability to choose treatments.
Ledford H
Nature; 2020 Apr; 580(7803):311-312. PubMed ID: 32273618
[No Abstract] [Full Text] [Related]
13. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs.
Conti A; Lasagni C; Bigi L; Pellacani G
J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):e360-e361. PubMed ID: 32379913
[No Abstract] [Full Text] [Related]
14. Kidney Transplantation and COVID-19.
Merhi B; Gohh R
R I Med J (2013); 2020 Sep; 103(8):34-37. PubMed ID: 32900010
[No Abstract] [Full Text] [Related]
15. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
16. May IL-17 have a role in COVID-19 infection?
Megna M; Napolitano M; Fabbrocini G
Med Hypotheses; 2020 Jul; 140():109749. PubMed ID: 32339777
[No Abstract] [Full Text] [Related]
17. COVID-19 as a cause of immune thrombocytopenia.
Humbert S; Razanamahery J; Payet-Revest C; Bouiller K; Chirouze C
Med Mal Infect; 2020 Aug; 50(5):459-460. PubMed ID: 32445664
[No Abstract] [Full Text] [Related]
18. Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.
Georgakopoulos JR; Mufti A; Vender R; Yeung J
J Am Acad Dermatol; 2020 Oct; 83(4):1212-1214. PubMed ID: 32679279
[No Abstract] [Full Text] [Related]
19. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Gisondi P; Facheris P; Dapavo P; Piaserico S; Conti A; Naldi L; Cazzaniga S; Malagoli P; Costanzo A
Br J Dermatol; 2020 Aug; 183(2):373-374. PubMed ID: 32343839
[No Abstract] [Full Text] [Related]
20. Covid-19-The real role of NSAIDs in Italy.
de Girolamo L; Peretti GM; Maffulli N; Brini AT
J Orthop Surg Res; 2020 May; 15(1):165. PubMed ID: 32366317
[No Abstract] [Full Text] [Related]
[Next] [New Search]
